FindTrial
Sign In

Tofogliflozin

DRUG5 trials

Sponsors

Kowa Research Institute Inc., Matsuba Medical Clinic, Kowa Company, Ltd., Kanazawa University, Shinshu University

Conditions

MetforminNon-alcoholic Fatty Liver DiseaseNoncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver FibrosisSGLT2-InhibitorsT2DM (Type 2 Diabetes Mellitus)Type 2 Diabetes MellitusType 2 diabetes

Phase 2

Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)
RecruitingNCT05469659
Shinshu UniversityMetformin, SGLT2-Inhibitors, T2DM (Type 2 Diabetes Mellitus)
Start: 2021-09-22End: 2026-10-30Target: 120Updated: 2022-07-22
A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis
Active, not recruitingCTIS2023-508104-38-00
Kowa Research Institute Inc.Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis
Start: 2023-02-16Target: 16Updated: 2025-04-09

Phase 4

Tofogliflozin GLP-1 Analogue Combination Trial
CompletedNCT02537834
Kowa Company, Ltd.Type 2 Diabetes Mellitus
Start: 2015-08-31End: 2017-10-31Updated: 2020-11-17
SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD
CompletedNCT02649465
Kanazawa UniversityNon-alcoholic Fatty Liver Disease
Start: 2015-11-11End: 2021-06-30Updated: 2021-07-02

Unknown Phase

Effect on Insulin Resistance in Tofogliflozin-treated Japanese Type 2 diabetic patients
Active, not recruitingJPRN-UMIN000017006
Matsuba Medical ClinicType 2 diabetes
Start: 2015-04-17Target: 15Updated: 2026-06-29

Related Papers

Tofogliflozin alters amino acid metabolism in gut microbiota linked to hepatic transcriptomic signatures in MASLD.
2026-07-30
Effect of Tofogliflozin on Urinary Albumin-to-Creatinine Ratio vs. Metformin in Diabetic Kidney Disease: Rationale and Study Protocol of the TRUTH-DKD Trial.
2025-11-18
Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
2020-01-206 citations